Insilico (03696) announced its 2025 financial results on March 29, 2026. The company listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, achieving the largest fundraising scale among biopharmaceutical IPOs on the Hong Kong stock market for that year. By the end of 2025, cash and bank balances reached $393 million, with annual revenue totaling $56.24 million.

On the platform front, the company completed upgrades across the three core modules of its Pharma.AI platform—Biology, Chemistry, and Science—and launched TargetBench 1.0, a benchmark for target discovery; Nach01, a multimodal chemical foundation model; and MMAI Gym, a training framework for large models.

In R&D, the company nominated six preclinical candidate drugs throughout the year and advanced eight projects into clinical stages. In terms of R&D collaborations, over 10 new partnerships were established, with a total value of $1.3 billion. Multiple projects also achieved milestones and generated revenue.